A large-scale study has found that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) like Wegovy and Ozempic may significantly increase the risk of depression, anxiety, and suicidal behaviorĀ in patients with obesity. Key findings include:
šĀ Risks Associated with GLP-1 RAs:
195% higher risk of major depression
108% higher risk of anxiety
106% higher risk of suicidal ideation/attempts
ā³Ā Longer Use = Higher RiskThe risks grow with prolonged use, especially with higher doses like Wegovy (Semaglutide 2.4 mg).
ā ļøĀ Who's Most Affected?
Women and younger adults (18ā49) face the highest risks.
Black patients showed the greatest risk for anxiety and suicidal ideation.
š§ Ā Why?
GLP-1 RAs might affect dopamine regulation in the brain, disrupting mood and mental health.
š©āāļøĀ What You Should Do:
If you're using or considering GLP-1 RAs for weight management, talk to your doctor about your mental health historyĀ and any potential risks. š¬
This study highlights the need for careful evaluation and further researchĀ to ensure these medications are used safely.
šĀ Kornelius, E., et al., The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy. Scientific Reports, 2024. 14(1): p. 24433.
Comments